Patentees Get Boost With China's Version Of Hatch-Waxman
A new Chinese litigation system for drug patents that is modeled on the U.S. Hatch-Waxman Act could be a boon for branded drugmakers by resolving infringement disputes before generic products launch,...To view the full article, register now.
Already a subscriber? Click here to view full article